Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 869-871, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sampson, M. L.
Right arrow Articles by Remaley, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sampson, M. L.
Right arrow Articles by Remaley, A. T.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2000;46:869-871.)
© 2000 American Association for Clinical Chemistry, Inc.

Technical Briefs

Estimation of Serum Apolipoprotein B by a Modified Homogeneous Assay for HDL-Cholesterol,

Maureen L. Sampson1, Gyorgy Csako1 and Alan T. Remaleya,1

1 Clinical Pathology Department, Clinical Center, National Institutes of Health, Bldg. 10, Rm. 2C-407, Bethesda, MD 20892-1508
a author for correspondence: fax 301-402-1885, e-mail aremaley@nih.gov

Serum lipoprotein analysis frequently is used in assessing the risk for coronary artery disease and for monitoring cholesterol-lowering therapy (1)(2). A recent improvement in the analysis of lipoproteins is the development of homogeneous assays for HDL-cholesterol (HDL-C) (3)(4) that are easier to perform because they do not require the physical separation of the apolipoprotein B (apoB)-containing lipoproteins by precipitation and centrifugation. The measurement of LDL-cholesterol (LDL-C) and apoB, the principal protein on LDL, is also useful for estimating the risk for cardiovascular risk (1)(2). An isolated increase in apoB in the absence of increased total cholesterol and LDL-C is diagnostic for a risk condition called hyperapoB-lipoproteinemia (5). We describe a simple modification of an antibody-based commercial homogeneous assay for HDL-C (EZ-HDL; Sigma Diagnostics) that in addition to measuring HDL-C, also provides an estimate of the apoB concentration.

In step 1 of the EZ-HDL assay, an anti-apoB antibody is added, which binds to . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. L. Sampson, A. Aubry, G. Csako, and A. T. Remaley
Triple Lipid Screening Test: A Homogeneous Sequential Assay for HDL-Cholesterol, Total Cholesterol, and Triglycerides
Clin. Chem., March 1, 2001; 47(3): 532 - 539.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.